Johnson & Johnson Family of Companies
NEWS
The FDA informed Johnson & Johnson that adverse-event reports indicated a possible increased risk of immune thrombocytopenia within 42 days after vaccination with their COVID-19 vaccine.
As the Omicron strain sweeps the world, researchers rush to determine how effective vaccines are at creating immunity against the variant. For that and more, continue reading.
Teva Pharmaceuticals will appeal a potential $1.5 billion judgment against the company in the state of New York for its alleged role in the opioid epidemic.
New Year is coming, and COVID-19 is still at play. For more COVID-19 studies, vaccines, and treatments, here are the latest updates.
As the spread of the Omicron variant of COVID-19 picks up speed, vaccine makers are rushing to test their shots against the new mutation, with mixed results.
In a unanimous vote made by U.S. health officials, the advisers decided the safer Pfizer and Moderna vaccines should be given as boosters.
A recent study estimates that in the U.S. alone the vaccines saved 1.1 million lives and prevented 10.3 million hospitalizations. For that and more COVID-19 news, continue reading.
Although it’s not yet clear how dangerous the Omicron variant of COVID-19 actually is, it clearly is very infectious and rates are rising in the U.S. and around the world.
Despite the biggest vaccination drive in the U.S., the pandemic is still not over. The U.S. has reported more than 800,000 COVID-19 deaths, an increase of 500,000 since the vaccination started.
JOBS
IN THE PRESS